These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16966723)

  • 1. The intersection of biotechnology and pharmacogenomics: health policy implications.
    Phillips KA
    Health Aff (Millwood); 2006; 25(5):1271-80. PubMed ID: 16966723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.
    Garrison LP; Austin MJ
    Health Aff (Millwood); 2006; 25(5):1281-90. PubMed ID: 16966724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will pharmacogenomics disrupt the U.S. health care system? No.
    Garrison LP
    Public Health Genomics; 2009; 12(3):185-90. PubMed ID: 19204422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
    Issa AM
    Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How molecular medicine transforms policy (and everything else).
    Kean MA; Batchelder KF
    J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and the challenge of health disparities.
    Lee SS
    Public Health Genomics; 2009; 12(3):170-9. PubMed ID: 19204420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
    Phillips KA; Veenstra DL; Ramsey SD; Van Bebber SL; Sakowski J
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):425-32. PubMed ID: 15298364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges.
    Deverka PA; Doksum T; Carlson RJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):427-34. PubMed ID: 17687271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BeadArray-based solutions for enabling the promise of pharmacogenomics.
    Fan JB; Hu SX; Craumer WC; Barker DL
    Biotechniques; 2005 Oct; 39(4):583-8. PubMed ID: 16235573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery systems - an overview.
    Jain KK
    Methods Mol Biol; 2008; 437():1-50. PubMed ID: 18369961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key aspects of health system change on the path to personalized medicine.
    Downing GJ
    Transl Res; 2009 Dec; 154(6):272-6. PubMed ID: 19931192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive public policy for genomics.
    Carlson RJ
    J Health Polit Policy Law; 2008 Feb; 33(1):39-51. PubMed ID: 18252856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotechnology and Medicare's new technology policy: lessons from three case studies.
    Keenan PS; Neumann PJ; Phillips KA
    Health Aff (Millwood); 2006; 25(5):1260-9. PubMed ID: 16966721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ancillary risk information and pharmacogenetic tests: social and policy implications.
    Henrikson NB; Burke W; Veenstra DL
    Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.